Weight management peptides (GLP-1s) benefit from solid clinical evidence, whereas so-called regenerative peptides (such as BPC-157 or TB-500) lack sufficient human data and present safety risks linked to their sourcing outside of official channels.

noli's read

Andrew Huberman is entirely correct regarding GLP-1s: their efficacy in weight management and cardiovascular health is solidly validated by meta-analyses of randomized clinical trials (such as the comprehensive analysis published in *The BMJ*). Likewise, his warning about regenerative peptides (BPC-157, TB-500) is scientifically well-founded, as human efficacy data remains extremely limited. A recent narrative review by a sports medicine expert at the University of Southern California (USC) confirms that the benefits of these molecules for tissue repair rely almost exclusively on animal models. Security concerns are also real: evaluation reports from the FDA's expert committee highlight risks of impurities and immunogenic reactions linked to the non-standardized manufacturing of these peptides. Conversely, the mentioned rumors regarding a general decline in motivation induced by GLP-1s currently remain anecdotal observations without robust clinical proof. As this market is undergoing significant regulatory changes, caution remains advisable.

the sources

1. 1Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS 2010
2. 2Wilding JPH et al. (STEP 1) 2021
3. 3Jastreboff AM et al. (SURMOUNT-1) 2022
4. 4Jastreboff AM et al. 2023
5. 5Wilding JPH et al. (STEP 1 extension) 2022